- Home
- ORKT vs VYNE Comparison
ORKT vs VYNE Comparison
Compare ORKT & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKT
- VYNE
- Stock Information
- Founded
- ORKT 2003
- VYNE 2003
- Country
- ORKT Singapore
- VYNE United States
- Employees
- ORKT N/A
- VYNE N/A
- Industry
- ORKT
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- ORKT
- VYNE Health Care
- Exchange
- ORKT NYSE
- VYNE Nasdaq
- Market Cap
- ORKT 34.7M
- VYNE 35.7M
- IPO Year
- ORKT 2024
- VYNE 2018
- Fundamental
- Price
- ORKT $1.10
- VYNE $2.74
- Analyst Decision
- ORKT Strong Buy
- VYNE Strong Buy
- Analyst Count
- ORKT 1
- VYNE 2
- Target Price
- ORKT $5.00
- VYNE $6.88
- AVG Volume (30 Days)
- ORKT 5.4M
- VYNE 84.7K
- Earning Date
- ORKT 10-16-2024
- VYNE 02-27-2025
- Dividend Yield
- ORKT N/A
- VYNE N/A
- EPS Growth
- ORKT N/A
- VYNE N/A
- EPS
- ORKT N/A
- VYNE N/A
- Revenue
- ORKT $3,904,592.00
- VYNE $493,000.00
- Revenue This Year
- ORKT N/A
- VYNE $28.30
- Revenue Next Year
- ORKT N/A
- VYNE N/A
- P/E Ratio
- ORKT N/A
- VYNE N/A
- Revenue Growth
- ORKT N/A
- VYNE 39.27
- 52 Week Low
- ORKT $0.62
- VYNE $1.57
- 52 Week High
- ORKT $8.00
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- ORKT N/A
- VYNE 56.12
- Support Level
- ORKT N/A
- VYNE $2.39
- Resistance Level
- ORKT N/A
- VYNE $2.65
- Average True Range (ATR)
- ORKT 0.00
- VYNE 0.20
- MACD
- ORKT 0.00
- VYNE 0.05
- Stochastic Oscillator
- ORKT 0.00
- VYNE 71.01
About ORKT ORANGEKLOUD TECHNOLOGY INC
Orangekloud Technology Inc is a company that operates through its subsidiaries provide IT consultancy services and distribution of related products and services. The Company also offers ERPs predominately in Singapore. It derives revenue from platform subscriptions, license and products and professional services.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.